One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
High-priority historical-source disagreement. Large pre/post-HD doses and per-dose versus per-day wording are retained exactly in meaning to expose the original discrepancy, not endorsed as a current regimen. Use a current indication-specific source before prescribing.
NIH PCP treatment and Nebraska specialist alternatives at very low kidney function are not the same as the manufacturer general not-recommended restriction. Doses expressed as mg/kg refer to trimethoprim, not combined TMP-SMX mass.
The oral mirror expresses renal adjustment as a proportion of the indication-specific regimen. Renal impairment also increases potassium-monitoring relevance.
What to reconcile: Review indication, trimethoprim amount, potassium and interactions. Do not generate an IV or Pneumocystis regimen from this fraction alone.
Open this note and its source referencesThe article's final summary uses CrCl >30 mL/min for standard indication-specific dosing, 15-30 for half the usual dose, and <15 for the FDA not-recommended category. Its embedded tables incorrectly print "<30" beside standard dosing, conflicting with that final summary; this discrepancy is not copied as a usable threshold.
Nebraska's separately described institutional alternative for CrCl <15 is 25-50% of the indication-specific total daily dose, with caution and monitoring; on HD days administer after dialysis. This is not the FDA recommendation.
Monitor potassium, sodium and kidney function. Trimethoprim can cause hyperkalemia/hyponatremia, while sulfamethoxazole metabolites can contribute to crystal-associated kidney injury. The article's modality-specific alternative doses are not generalized here because indication and dialysis details matter.
RDM30-094-tmp-smx-1 · Source locator: Nebraska - TMP/SMX renal adjustment and source inconsistency; renal/dosing sections and stated qualifiers
Source contains an internal inequality inconsistency. Institutional alternatives and FDA-described restrictions are distinct.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=tmp-smx&s1=RDM30-094-tmp-smx&h1=73af94eea5a0747ebd6450f522e71a943866d26220f7071ad05b2dff4e44455f